Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 8/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.49 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134395 | 0.93 | MAPKAPK5 (0.56) | MAPKAPK5MAPK10MAPK9SYKHTT | |
| SCHEMBL10134365 | 0.90 | MAPKAPK5 (0.58) | MAPKAPK5MAPK10MAPK9SYKHTT | |
| SCHEMBL13922426 | 0.87 | MAPKAPK5 (0.49) | MAPKAPK5MAPK10MAPK9SYKHTT | |
| SCHEMBL12618516 | 0.85 | HTT (0.46) | MAPKAPK5MAPK10MAPK9HTTJAK2 | |
| SCHEMBL12618581 | 0.84 | MAPKAPK5 (0.67) | MAPKAPK5MAPK10MAPK9 | |
| SCHEMBL12618515 | 0.83 | MAPKAPK5 (0.44) | MAPKAPK5MAPK10MAPK9HTTJAK2 | |
| SCHEMBL12618537 | 0.83 | MAPKAPK5 (0.45) | MAPKAPK5MAPK10MAPK9HTTJAK2 | |
| SCHEMBL12618541 | 0.83 | MAPKAPK5 (0.45) | MAPKAPK5MAPK10MAPK9HTTJAK2 | |
| SCHEMBL10134359 | 0.82 | MAPKAPK5 (0.59) | MAPKAPK5MAPK10MAPK9SYKHTT | |
| SCHEMBL10134591 | 0.80 | MAPKAPK5 (0.46) | MAPKAPK5JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885MAPK10 486/4885MAPK9 303/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 19/4885MAPK10 486/4885MAPK9 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.